caa a22 4500 475833120 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1023/A:1007895222149 doi (NATIONALLICENCE)springer-10.1023/A:1007895222149 Guanabenz Combination Therapy Inhibits Sympathetic Nerve Activity and Regresses Left Ventricular Hypertrophy [Elektronische Daten] [Eiji Miyajima, Tomohiko Shigemasa, Tsutomu Endo, Satoru Hishiki, Yoshiyuki Kawano] The cardiovascular and sympatholytic effects of combination therapy with guanabenz were examined in 26 patients (48 ± 13 years old [mean ± SD]) with stage 2 and 3 hypertension. Included in the study were patients under treatment with conventional antihypertensive drugs whose systolic and diastolic blood pressure was above 140 and 90 mmHg, respectively. Blood pressure, heart rate, and sympathetic parameters such as plasma concentration of norepinephrine and muscle sympathetic nerve activity at rest as well as during ambulatory conditions, 24-hour urinary excretion of norepinephrine, and low frequency (LF: 0.04-0.15 Hz)/high frequency (HF: 0.15-0.4 Hz) power ratio as a marker of cardiac sympathetic activity during 24 hours were examined before and after guanabenz (4-8 mg/d) combination therapy with first-line antihypertensive drugs such as diuretics. Left ventricular mass index (LVMI) was also calculated by conventional echocardiography. After 32 weeks of guanabenz combination therapy, systolic and diastolic blood pressure, heart rate, plasma and urinary excretion of norepinephrine, muscle sympathetic nerve activity, and LF/HF power ratio were significantly decreased, while neither LF nor HF power was changed. LVMI was also significantly decreased (270 ± 81 vs. 236 ± 83 g/m2, p < 0.005). These results indicate that guanabenz combination therapy inhibits sympathetic nerve activity under resting conditions as well as during ambulatory conditions and may accelerate regression of left ventricular hypertrophy in patients with moderate to severe hypertension. Kluwer Academic Publishers, 2000 α2-agonist nationallicence essential hypertension nationallicence heart rate variability nationallicence muscle sympathetic nerve activity nationallicence norepinephrine nationallicence Miyajima Eiji Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut Shigemasa Tomohiko Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut Endo Tsutomu Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut Hishiki Satoru Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut Kawano Yoshiyuki Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 61-66 0920-3206 14:1<61 2000 14 10557 https://doi.org/10.1023/A:1007895222149 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007895222149 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Miyajima Eiji Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut NATIONALLICENCE 700 1- Shigemasa Tomohiko Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut NATIONALLICENCE 700 1- Endo Tsutomu Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut NATIONALLICENCE 700 1- Hishiki Satoru Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut NATIONALLICENCE 700 1- Kawano Yoshiyuki Yokohama City University School of Medicine, Medical Center, Yokohama, Japan aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 61-66 0920-3206 14:1<61 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer